Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price traded up 22.4% during trading on Friday . The stock traded as high as $0.41 and last traded at $0.40. 60,477,578 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 79,476,109 shares. The stock had previously closed at $0.33.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Saturday. They issued a "hold" rating for the company.
Get Our Latest Stock Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Up 17.0 %
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market capitalization of $71.60 million, a P/E ratio of -0.01 and a beta of 2.02. The company has a 50-day simple moving average of $0.28 and a 200 day simple moving average of $0.28.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company's stock.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
